Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

EXTON, Pa., Sept. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI), a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.  VP20621 contains the spores of a naturally occurring non-toxin producing strain of C. difficile.  

The poster entitled 'Phase 1 Evaluation of an Oral Suspension of VP 20621, Spores of a Non-Toxigenic C. difficile Strain (NTCD), in Healthy Older Subjects Pretreated With Oral Vancomycin' is being presented today at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in poster session F1-2127b by Stephen Villano, M.D., ViroPharma's vice president of clinical research and development.

The Phase 1 study was designed to determine the safety and tolerability of VP20621 dosed orally as single and repeat escalating doses in healthy young (18 to 45 years of age) and older (60 years of age and older) adults.  Because VP20621 was shown to be well tolerated following single and repeat doses in younger and older healthy subjects, the company also performed repeat dosing in older adults following exposure to oral antibiotic.  The new data presented today was from healthy subjects above 60 years of age who were pre-dosed with oral vancomycin to disrupt their gastrointestinal flora and render them potentially susceptible to C. difficile colonization. Subjects were subsequently given either placebo or VP20621 doses of 10(4),10(6), or 10(8) spores (once daily for 14 days).  Conclusions from the study include:

  • Multiple doses of VP20621 were ge
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... SUNNYVALE, Calif. , June 19, 2013 ... today announced that The New England Journal of ... a Phase 1b/2 study evaluating the investigational oral Bruton,s ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ... patients with relapsed/refractory CLL or SLL, even in patients ...
(Date:6/19/2013)... CHICAGO , June 19, 2013 The Physician-Patient ... reduce alarm fatigue. The need to urgently address ... in its Sentinel Event Alert #50 , "Medical device alarm ... Alert database, between January 2008 and June 2012, there were ... 80 resulted in death (82%) , 13 resulted in ...
(Date:6/19/2013)...   Voices Against Brain Cancer (VABC), a ... cancer, today announced that it has awarded Tocagen Inc. ... investigation of Toca 511 & Toca FC in patients ... (Grade 3 or Grade 4).  Tocagen is a privately ... with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
(Date:6/19/2013)... (PRWEB) June 19, 2013 The ... program is this Friday, June 21 at midnight ... ongoing programs and innovative people who’ve raised the ... information, visit http://www.minonline.com/ima . , Any consumer ... magazine title is eligible to enter. Additionally, advertising ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... early April, senior leaders from medical, law enforcement, military, ... one question: how can first responders improve survival after ... results of this discussion are now available in " ... ," a concept paper published in the June issue ... Acute Care Surgery , official publication of the ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... are supporting WaterAid to deliver the most wished for Christmas present in ... ... Bendalls are appealing to social media groups, the Australian blog community and ... donate and download a e-Christmas Card , with a personalized message. ...
... scientists and the news media have evolved tremendously over ... improve communications with both the media and the lay ... commentary appears this month in a major scientific journal. ... and pharmacology at Wake Forest University School of Medicine, ...
... white women to have reconstruction after mastectomy , , MONDAY, ... women are more likely to have immediate breast reconstruction ... , This is also true for more educated women ... black women and those who live in predominantly black ...
... found little link between drinking and malignancies , , MONDAY, ... your chances of developing cancer after age 65, new ... lack of physical activity were among the usual suspects ... to the Duke University study. , The findings are ...
... nanoparticles and polymer carriers as potential new techniques ... and blindness in the United States, according to ... Research Institute Conference. , The report ( http://www.iovs.org/cgi/content/full/49/11/4712 ... for ocular drug delivery to the posterior segment ...
... LAKE CITY Nov. 17, 2008 Researchers at the ... trial that uses a patient,s own stem cells to treat ... Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study ... (CRC) and their ability to improve heart function. , Patients ...
Cached Medicine News:Health News:Urgent Request for Water 2Health News:Award-winning researcher says relationships with news media, public are critical 2Health News:Award-winning researcher says relationships with news media, public are critical 3Health News:Wealthy More Likely to Have Breast Reconstruction 2Health News:Stay Upbeat, Exercise to Help Prevent Cancer in Old Age 2Health News:Conference report highlights new research into drug delivery to treat eye disease 2Health News:U of U researchers to use patient's own stem cells to treat heart failure 2
Post-Surgical compression garments...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... menu includes kits that quantitatively measure two ... (a). An elevated serum or plasma homocysteine ... and independent risk factor for cardiovascular disease. ... have associated elevated levels of Lp(a) with ...
Medicine Products: